Longevity Healthcare model basket

Oncology Platforms

Large-cap pharma oncology franchises trading at a discount that already assumes successor failure.

What is the thesis for Oncology Platforms?

We own the diversified oncology and specialty-pharma cohort whose multiples embed a near-worst-case outcome for immuno-oncology franchise succession. The thesis rests on reference-class evidence that major IO and targeted-therapy programs generate successor molecules at rates well above the consensus-implied probability, and that big-cap pharma balance sheets absorb patent-cliff risk with ample room for continued capital return.

This is a curated QuantLink model basket. It is not a filed portfolio, not a fund, and not investment advice.

Published Apr 14, 2026. Updated Apr 14, 2026. Source: QuantLink curated model basket and FastAPI ideas endpoint.

Holdings
12
Benchmark
SPY
Status
New
1Y model return
+32.0%

Performance as of Nov 22, 2026.

Thesis narrative

The question

Are big-cap pharma oncology franchises priced for a successful succession off the 2028-2030 Keytruda cliff, or for a near-total revenue gap with no offset from the subcutaneous reformulation, combination label extensions, or the successor IO and ADC pipelines?

Base rates

Healthcare has trailed SPY materially over the trailing twelve months, and large-cap pharma has been the worst-performing sector cohort within healthcare. The gap is the opportunity, not the warning. The reference class is prior blockbuster patent cliffs where the incumbent franchise holder owned the successor molecule or reformulation: Lipitor to Crestor-era statin succession, Humira to IL-23 and IL-17 class succession, and Gleevec to second-generation TKIs. In each case, the incumbent lost thirty to fifty percent of peak revenue on the core molecule and retained sixty to eighty percent of peak franchise economics through reformulation, combination, and successor label.

The relevant conditional probability is that a sponsor with an approved anti-PD-1 backbone and an active ADC or bispecific combination program will generate at least one successor approval within the thirty-six months surrounding loss of exclusivity. Across the last two decades of oncology data, that conditional probability has been roughly sixty-five to seventy-five percent. The consensus discount embedded in Merck's current multiple implies a probability closer to twenty-five percent.

For the basket, median forward P/E sits roughly four turns below the fifteen-year median, dividend coverage is intact, and free-cash-flow conversion remains above eighty percent across all seven large-cap holdings. The base rate for a diversified pharma basket at a four-turn discount with intact coverage and visible pipeline is a low-teens three-year annualized total return, versus high-single-digits for the market.

Why consensus is wrong

The sell-side oncology model is built around single-asset succession probabilities applied independently. That structure understates the franchise economics in two ways.

First, Keytruda's subcutaneous reformulation, if approved on the current timeline, retains a meaningful share of the injectable franchise through post-2028 formulation exclusivity. The market is modeling a binary cliff; the actual outcome is a staircase. Staircases are worth substantially more than cliffs in a DCF, and the re-rating when the timeline becomes visible to the sell-side is mechanical.

Second, combination-with-successor labels are a well-established path to extend franchise economics. AstraZeneca's Tagrisso-plus-chemo, Merck's Keytruda-plus-Lynparza, and Bristol's Opdualag all demonstrate that the incumbent franchise holder has structural advantages in combination development: real-world data on the backbone, established prescriber relationships, and commercial infrastructure. The probability of at least one major combination approval extending franchise economics past 2030 is substantially higher than the probability applied to any individual successor asset.

Third, the ADC and bispecific pipelines at AstraZeneca, Johnson & Johnson, and Merck have advanced far enough that several readouts in 2026-2027 will force a re-rating regardless of Keytruda timing. The market has priced those readouts as low-probability binary events; the clinical data support a higher base rate for at least one approval across the cohort.

Position construction

The book has three twenty-percent anchors and two sub-books.

Anchors. Johnson & Johnson at twenty percent captures the broadest oncology franchise exposure across Darzalex, Carvykti, and the emerging bispecific pipeline, with the consumer-health separation providing a cleaner pharma-only valuation look. AstraZeneca at twenty percent is the purest ADC play at scale -- Enhertu, Datroway, and the broader Daiichi partnership produce the strongest pipeline depth in the cohort. Novartis at twenty percent owns Pluvicto, Kisqali, and a focused radiopharmaceutical build-out that is still under-appreciated by the market.

Core large-cap, roughly twenty-five percent. Merck at ~17.0% is the central Keytruda-succession position; Bristol-Myers Squibb at ~7.1% adds Opdivo, Breyanzi, and a cardiovascular-adjacent pipeline at the steepest discount in the basket.

Diversifiers and specialty, roughly fifteen percent. Vertex at ~8.6% is the cystic-fibrosis monopoly and emerging pain and nephrology expansion, uncorrelated to IO dynamics. Takeda at ~3.6% adds a hematology and rare-disease franchise with a dividend floor. Neurocrine at ~1.1%, Jazz at ~0.7%, Exelixis at ~0.9%, and Roivant at ~1.0% are specialty-pharma positions with their own catalysts. Denali at ~0.2% is a small asymmetric exposure to neurodegeneration.

Asymmetric payoff

If Keytruda subcutaneous is approved on timeline and at least one ADC or combination label expansion clears in the basket over the next eighteen months, the book returns roughly 15-24% annualized over three years as the multiple re-rates toward the fifteen-year median. If the Keytruda cliff plays out closer to consensus and two or more pipeline assets fail, the book returns roughly -2% to +4% with dividend income absorbing most of the multiple pressure. If radiopharma or ADC data read through to a category-wide re-rating, the right tail is 28-38%.

At a 55% base, 25% bear, 20% bull weighting, expected value is roughly +12 to +16% annualized against an SPY base rate near +8%. The asymmetry comes from the fact that the current multiple already assumes the bear case.

Three things that would change our mind

  1. The FDA declining to approve the Keytruda subcutaneous reformulation or issuing a narrow label that caps pricing parity with the IV form, which would convert the staircase back into a cliff.
  2. Two or more top-ten ADC or bispecific pipeline readouts in the basket reading out below their Phase 2 efficacy benchmarks by more than thirty percent on the primary endpoint, indicating the successor probability we are betting on is materially below the historical base rate.
  3. A durable change in IRA-driven pricing rules that extends negotiation to the first nine years of branded exclusivity rather than the current window, which would compress franchise economics on every molecule in the book simultaneously.

What we're explicitly NOT betting on

We are not betting on a single molecule approval or a single readout. We are not betting on a specific M&A target being acquired at a specific premium. We are not betting on cell and gene therapy economics improving on the current trajectory -- that is a separate idea with different reference classes. We are not betting on small-cap biotech re-rating broadly; the XBI-cohort recovery is not the claim. The thesis requires only that the implied successor probability embedded in large-cap pharma multiples compresses toward the long-run reference class. That is a narrower claim than picking winners, and the book is sized for it.

Model basket holdings

Model basket: curated equal or target weighting, not a filed portfolio. Weights are the target basket weights returned by the live ideas endpoint.

NameSymbolModel weight
Johnson & JohnsonJNJ19.99%
AstraZeneca PLCAZN20.00%
Novartis AGNVS20.00%
Merck & Co., Inc.MRK16.99%
Vertex Pharmaceuticals IncorporatedVRTX8.57%
Bristol-Myers Squibb CompanyBMY7.12%
Takeda Pharmaceutical Company LimitedTAK3.56%
Denali Therapeutics Inc.DNLI0.20%
Neurocrine Biosciences, Inc.NBIX1.11%
Roivant Sciences Ltd.ROIV0.95%
Exelixis, Inc.EXEL0.85%
Jazz Pharmaceuticals plcJAZZ0.66%

Backtested performance vs SPY

Performance is backtested from the returned tearsheet series. It reflects the model basket methodology and benchmark series, not live fund returns or a filed portfolio track record. Performance as of Nov 22, 2026.

Total Return

+32.0%

↑ SPY +3.2%

Ann. Return

+33.5%

↑ SPY +3.3%

Ann. Vol

30.9%

↑ SPY 14.5%

Sharpe

1.08

↑ SPY 0.23

Max Drawdown

-11.5%

↓ SPY -11.5%

Alpha vs SPY

+33.3%

↓ hit rate 48.3%

Performance as of Nov 22, 2026. Risk-free rate for Sharpe and Sortino: 0% (no risk-free rate applied).

Rolling Performance vs Benchmark

Portfolio Holdings

Holding
Weight
Country
Exchange
Sector
Industry
Mkt Cap
Price
1Y
1Y Trend
AZN
AZNAstraZeneca PLC
20.0%
—
—
—
—
—
—
—
NVS
NVSNovartis AG
20.0%
—
—
—
—
—
—
—
JNJ
JNJJohnson & Johnson
20.0%
—
—
—
—
—
—
—
MRK
MRKMerck & Co., Inc.
17.0%
—
—
—
—
—
—
—
VRTX
VRTXVertex Pharmaceuticals Incorporated
8.6%
—
—
—
—
—
—
—
BMY
BMYBristol-Myers Squibb Company
7.1%
—
—
—
—
—
—
—
TAK
TAKTakeda Pharmaceutical Company Limited
3.6%
—
—
—
—
—
—
—
NBIX
NBIXNeurocrine Biosciences, Inc.
1.1%
—
—
—
—
—
—
—
ROIV
ROIVRoivant Sciences Ltd.
0.9%
—
—
—
—
—
—
—
EXEL
EXELExelixis, Inc.
0.8%
—
—
—
—
—
—
—
JAZZ
JAZZJazz Pharmaceuticals plc
0.7%
—
—
—
—
—
—
—
DNLI
DNLIDenali Therapeutics Inc.
0.2%
—
—
—
—
—
—
—

SSR performance series fallback

The table below is the server-rendered reference series behind the interactive chart. Values show the wealth index level from a 1.00 starting value, not a second 1Y return figure. Series as of Nov 22, 2026.

DateModel basket wealth indexSPY
Nov 25, 20251.0000x1.0000x
Nov 26, 20251.0019x1.0069x
Nov 28, 20250.9964x1.0124x
Dec 1, 20250.9819x1.0078x
Dec 2, 20250.9839x1.0096x
Dec 3, 20251.0029x1.0131x
Dec 4, 20250.9967x1.0139x
Dec 5, 20250.9895x1.0158x
Dec 8, 20250.9829x1.0128x
Dec 9, 20250.9743x1.0119x
Dec 10, 20250.9875x1.0186x
Dec 11, 20250.9957x1.0210x
Dec 12, 20251.0027x1.0100x
Dec 15, 20251.0152x1.0085x
Dec 16, 20251.0066x1.0057x
Dec 17, 20251.0073x0.9946x
Dec 18, 20251.0037x1.0021x
Dec 19, 20251.0084x1.0083x
Dec 22, 20251.0189x1.0145x
Dec 23, 20251.0239x1.0192x
Dec 24, 20251.0333x1.0228x
Dec 26, 20251.0281x1.0227x
Dec 29, 20251.0328x1.0190x
Dec 30, 20251.0218x1.0178x
Dec 31, 20251.0128x1.0102x
Jan 2, 20260.9185x1.0121x
Jan 5, 20260.9140x1.0188x
Jan 6, 20260.9354x1.0249x
Jan 7, 20260.9441x1.0216x
Jan 8, 20260.9396x1.0215x
Jan 9, 20260.9380x1.0282x
Jan 12, 20260.9386x1.0298x
Jan 13, 20260.9413x1.0278x
Jan 14, 20260.9617x1.0227x
Jan 15, 20260.9509x1.0255x
Jan 16, 20260.9473x1.0247x
Jan 20, 20260.9367x1.0038x
Jan 21, 20260.9463x1.0154x
Jan 22, 20260.9479x1.0207x
Jan 23, 20260.9534x1.0211x
Jan 26, 20260.9604x1.0262x
Jan 27, 20260.9719x1.0303x
Jan 28, 20260.9613x1.0302x
Jan 30, 20261.1608x1.0251x
Feb 2, 20261.1785x1.0302x
Feb 3, 20261.1769x1.0215x
Feb 4, 20261.1952x1.0165x
Feb 5, 20261.2021x1.0039x
Feb 6, 20261.2310x1.0231x
Feb 9, 20261.2138x1.0280x
Feb 10, 20261.2197x1.0253x
Feb 11, 20261.2420x1.0251x
Feb 12, 20261.2466x1.0093x
Feb 13, 20261.2614x1.0100x
Feb 17, 20261.2678x1.0116x
Feb 18, 20261.2661x1.0167x
Feb 19, 20261.2673x1.0140x
Feb 20, 20261.2582x1.0213x
Feb 23, 20261.2710x1.0109x
Feb 24, 20261.2800x1.0183x
Feb 25, 20261.2746x1.0269x
Feb 26, 20261.2611x1.0212x
Feb 27, 20261.2911x1.0163x
Mar 2, 20261.2742x1.0168x
Mar 3, 20261.2572x1.0079x
Mar 4, 20261.2618x1.0150x
Mar 5, 20261.2291x1.0093x
Mar 6, 20261.2221x0.9961x
Mar 9, 20261.2347x1.0048x
Mar 10, 20261.2422x1.0032x
Mar 11, 20261.2270x1.0019x
Mar 12, 20261.2156x0.9867x
Mar 13, 20261.2082x0.9811x
Mar 16, 20261.2160x0.9911x
Mar 17, 20261.2106x0.9937x
Mar 18, 20261.1916x0.9799x
Mar 19, 20261.1893x0.9775x
Mar 20, 20261.1741x0.9608x
Mar 23, 20261.1796x0.9709x
Mar 24, 20261.1839x0.9676x
Mar 25, 20261.2044x0.9730x
Mar 26, 20261.1961x0.9557x
Mar 27, 20261.1949x0.9394x
Mar 30, 20261.2099x0.9362x
Mar 31, 20261.2279x0.9634x
Apr 1, 20261.2394x0.9707x
Apr 2, 20261.2351x0.9716x
Apr 6, 20261.2274x0.9762x
Apr 7, 20261.2142x0.9766x
Apr 8, 20261.2398x1.0015x
Apr 9, 20261.2418x1.0072x
Apr 10, 20261.2284x1.0066x
Apr 13, 20261.2239x1.0164x
Apr 14, 20261.2289x1.0288x
Apr 15, 20261.2170x1.0369x
Apr 16, 20261.2032x1.0395x
Apr 17, 20261.2223x1.0520x
Apr 20, 20261.2054x1.0499x
Apr 21, 20261.1808x1.0431x
Apr 22, 20261.1778x1.0536x
Apr 23, 20261.1818x1.0495x
Apr 24, 20261.1649x1.0577x
Apr 27, 20261.1524x1.0595x
Apr 28, 20261.1576x1.0543x
Apr 29, 20261.1500x1.0542x
Apr 30, 20261.1665x1.0646x
May 1, 20261.1593x1.0676x
May 4, 20261.1541x1.0637x
May 5, 20261.1526x1.0722x
May 6, 20261.1652x1.0871x
May 7, 20261.1512x1.0838x
May 8, 20261.1511x1.0927x
May 11, 20261.1491x1.0952x
May 12, 20261.1668x1.0936x
May 13, 20261.1842x1.0997x
May 14, 20261.1808x1.1084x
May 15, 20261.1628x1.0950x
May 18, 20261.1716x1.0943x
May 19, 20261.1793x1.0870x
May 20, 20261.1818x1.0981x
May 21, 20261.1955x1.1003x
May 22, 20261.2060x1.1046x
May 26, 20261.1926x1.1120x
May 27, 20261.1935x1.1118x
May 28, 20261.1945x1.1179x
May 29, 20261.1852x1.1207x
Jun 1, 20261.1549x1.1237x
Jun 2, 20261.1434x1.1253x
Jun 3, 20261.1437x1.1174x
Jun 4, 20261.1807x1.1216x
Jun 5, 20261.1948x1.0926x
Jun 8, 20261.1784x1.0951x
Jun 9, 20261.1929x1.0919x
Jun 10, 20261.1817x1.0747x
Jun 11, 20261.2038x1.0929x
Jun 12, 20261.1976x1.0989x
Jun 15, 20261.1805x1.1182x
Jun 16, 20261.1809x1.1116x
Jun 17, 20261.1797x1.0977x
Jun 18, 20261.1580x1.1062x
Jun 22, 20261.1728x1.1028x
Jun 23, 20261.2041x1.0868x
Jun 24, 20261.2118x1.0862x
Jun 25, 20261.2318x1.0878x
Jun 26, 20261.2581x1.0800x
Jun 29, 20261.2747x1.0977x
Jun 30, 20261.2637x1.1063x
Jul 1, 20261.2447x1.1048x
Jul 2, 20261.2976x1.1033x
Jul 6, 20261.2739x1.1130x
Jul 7, 20261.2935x1.1077x
Jul 8, 20261.2702x1.1043x
Jul 9, 20261.2495x1.1136x
Jul 10, 20261.2304x1.1184x
Jul 13, 20261.2282x1.1098x
Jul 14, 20261.2020x1.1138x
Jul 15, 20261.2096x1.1182x
Jul 16, 20261.2288x1.1121x
Jul 17, 20261.2344x1.1011x
Jul 20, 20261.2096x1.0994x
Jul 21, 20261.2317x1.1085x
Jul 22, 20261.2339x1.1072x
Jul 23, 20261.2465x1.0936x
Jul 24, 20261.2540x1.0947x
Jul 27, 20261.2600x1.0949x
Jul 28, 20261.2775x1.0975x
Jul 29, 20261.2710x1.0806x
Jul 30, 20261.2594x1.0988x
Jul 31, 20261.2511x1.1067x
Aug 3, 20261.2222x1.1224x
Aug 4, 20261.2216x1.1427x
Aug 5, 20261.2343x1.1404x
Aug 6, 20261.2331x1.1386x
Aug 7, 20261.2452x1.1455x
Aug 10, 20261.2592x1.1452x
Aug 11, 20261.2463x1.1415x
Aug 12, 20261.2462x1.1444x
Aug 13, 20261.2474x1.1524x
Aug 14, 20261.2410x1.1501x
Aug 17, 20261.2487x1.1447x
Aug 18, 20261.2721x1.1369x
Aug 19, 20261.3269x1.1393x
Aug 20, 20261.3025x1.1297x
Aug 21, 20261.3209x1.1344x
Aug 24, 20261.3212x1.1310x
Aug 25, 20261.3408x1.1346x
Aug 26, 20261.3214x1.1349x
Aug 27, 20261.3032x1.1423x
Aug 28, 20261.2959x1.1397x
Aug 31, 20261.2902x1.1363x
Sep 1, 20261.3165x1.1285x
Sep 2, 20261.3273x1.1335x
Sep 3, 20261.3395x1.1454x
Sep 4, 20261.3199x1.1410x
Sep 8, 20261.2651x1.1347x
Sep 9, 20261.2546x1.1294x
Sep 10, 20261.2512x1.1227x
Sep 11, 20261.2498x1.1322x
Sep 14, 20261.2633x1.1272x
Sep 15, 20261.2564x1.1220x
Sep 16, 20261.2594x1.1171x
Sep 17, 20261.2757x1.1297x
Sep 18, 20261.2713x1.1284x
Sep 21, 20261.2783x1.1459x
Sep 22, 20261.2815x1.1457x
Sep 23, 20261.2693x1.1375x
Sep 24, 20261.2753x1.1365x
Sep 25, 20261.2868x1.1427x
Sep 28, 20261.2919x1.1342x
Sep 29, 20261.2804x1.1321x
Sep 30, 20261.2602x1.1298x
Oct 1, 20261.2375x1.1318x
Oct 2, 20261.2340x1.1402x
Oct 5, 20261.2198x1.1479x
Oct 6, 20261.2295x1.1542x
Oct 7, 20261.2420x1.1514x
Oct 8, 20261.2362x1.1465x
Oct 9, 20261.2494x1.1534x
Oct 12, 20261.2465x1.1527x
Oct 13, 20261.2130x1.1526x
Oct 14, 20261.2515x1.1401x
Oct 15, 20261.2672x1.1434x
Oct 16, 20261.2655x1.1307x
Oct 19, 20261.2570x1.1357x
Oct 20, 20261.2920x1.1393x
Oct 21, 20261.2942x1.1453x
Oct 22, 20261.3171x1.1318x
Oct 23, 20261.2946x1.1258x
Oct 26, 20261.2947x1.1338x
Oct 27, 20261.3017x1.1402x
Oct 28, 20261.3010x1.1441x
Nov 5, 20261.3594x1.0859x
Nov 9, 20261.3822x1.1151x
Nov 10, 20261.3753x1.1110x
Nov 11, 20261.3673x1.1256x
Nov 12, 20261.3655x1.1216x
Nov 13, 20261.3706x1.1176x
Nov 16, 20261.3596x1.0962x
Nov 17, 20261.3470x1.0851x
Nov 18, 20261.3173x1.0817x
Nov 19, 20261.2858x1.0605x
Nov 20, 20261.2871x1.0219x

Themes and category

Longevity HealthcareLongevity & HealthcareInnovation

Methodology and caveats

QuantLink fetches this idea from the live FastAPI ideas endpoints and renders the returned title, thesis, holdings, themes, benchmark, and tearsheet fields directly. Missing fields are left unavailable rather than fabricated.

Holdings are a curated model basket. They are not 13F filings, not insider filings, not adviser holdings, and not a claim that any person or fund owns the basket.

Backtested performance depends on the returned basket weights, benchmark, rebalancing assumptions, available price history, and calculation choices in the tearsheet endpoint. Backtests can differ materially from live results and do not include every cost, tax, capacity, liquidity, or execution constraint an investor may face.

Equal-weight and target-weight baskets can drift between rebalance points. Rebalancing can increase turnover, and concentrated thematic baskets can have higher drawdowns than a broad market benchmark.

Frequently asked questions

Research the stocks behind this idea

Use QuantLink's screener and company pages to inspect fundamentals, valuation, and market data after reviewing the public thesis.

Related links

QuantLink is a research tool, not investment advice. This page shows a curated model basket and backtested performance, not a filed portfolio, fund return, or recommendation to buy or sell securities.